Acceptance of Illness and Compliance with Therapeutic Recommendations in Patients with Hypertension

Agnieszka Pluta1, Beata Sulikowska2, Jacek Manitius2

  • 1Department of Preventive Nursing, Faculty of Health Sciences, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, 87-100 Toruń, Poland.

Insights

This study found that patients with arterial hypertension (AH) generally accept their illness well, though adherence to treatment varies. Men showed lower adherence, highlighting the need for targeted patient education and support for managing hypertension.

Area of Science:

  • Cardiology
  • Public Health
  • Psychosocial Medicine

Background:

  • Arterial hypertension (AH) is a prevalent cardiovascular disease globally and in Poland, posing significant health, economic, and social challenges.
  • Complications and treatment costs associated with AH underscore its importance as a public health issue.

Purpose of the Study:

  • To evaluate illness acceptance and adherence to therapeutic recommendations among patients diagnosed with arterial hypertension.
  • To identify factors influencing illness acceptance and medication adherence in hypertensive patients.

Main Methods:

  • A study involving 200 outpatient patients with AH (85 men, 115 women, mean age 49.1 ± 11.6).
  • Utilized standardized instruments: Acceptance of Illness Scale (AIS) and the 8-item Morisky Medication Adherence Scale (MMAS-8).
  • Employed author-designed questionnaires for sociodemographic and comorbidity data collection.

Main Results:

  • Illness acceptance was higher in men than women, decreased with age, and negatively correlated with antihypertensive therapy duration.
  • Illness acceptance was not influenced by comorbidities or sociodemographic factors like residence or professional activity.
  • Medication adherence increased with education level but did not correlate with the Acceptance of Illness Scale score.
  • Men exhibited lower adherence and compliance compared to women.
  • Overall, patients demonstrated a moderate level of adherence and compliance.

Conclusions:

  • Hypertensive patients generally exhibit good illness acceptance, but adherence to treatment recommendations is moderate.
  • Targeted educational interventions, support, and enhanced patient-physician cooperation are crucial for improving treatment adherence in AH management.
  • Gender differences in adherence necessitate tailored approaches in patient care for arterial hypertension.

Related Concept Videos

Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
222
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
404
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
146
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.5K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
311
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
732